Scinai Immunotherapeutics Secures Funding for Advanced Robotic Aseptic Manufacturing Platform Development

Robotic Aseptic Fill and Finish Platform Receives Major Support from Israel Innovation Authority

Scinai Immunotherapeutics Ltd. announces a significant advance in its manufacturing operations with expanded funding from the Israel Innovation Authority (IIA). The IIA grants a total budget of NIS 5 million, with around 66% of this classified as non-dilutive funding. This financial support enables Scinai to develop a sophisticated robotic aseptic fill and finish platform, which aims for completion by the third quarter of 2026. The robotic system will comply with the stringent EU GMP Annex 1 standards, a crucial milestone for any company looking to enhance its capabilities in sterile manufacturing. Such enhancements are vital in the biotechnology sector, particularly for the production of complex biologics whose safety and efficacy hinge on the quality of the manufacturing process.

This initiative is part of Scinai's broader strategy to modernize its Contract Development and Manufacturing Organization (CDMO) capabilities. Following the recent acquisition of Recipharm Israel Ltd. and the establishment of a strategic collaboration with the company, Scinai aims to create a cohesive two-site development and manufacturing platform. This integration allows for seamless transitions for clients from early clinical development to commercial production, leveraging Recipharm’s extensive global network. By streamlining these processes, Scinai is poised to significantly improve service delivery and operational efficiency, which is crucial as client needs become increasingly complex.

The implementation of a fully automated robotic-arm aseptic system holds promise for enhancing reproducibility and contamination control within Scinai's facility in Jerusalem. CEO Amir Reichman and COO Elad Mark express their commitment to disciplined capital allocation as they invest in next-generation sterile manufacturing capacities. Mark points out that the new system will substantially improve their capabilities in managing complex biologics programs, ensuring that they not only meet industry standards but also address the evolving demands of their client base. Additionally, Scinai keeps a close watch on a potential new IIA program designed to support industrial CAPEX investments, reflecting their ongoing commitment to expanding their operational footprint in the biotechnology sector.

In related developments, Scinai Immunotherapeutics emphasizes its commitment to quality and innovation amidst the growing demands in the biotech field. The recent initiatives, particularly surrounding the robotic system, illustrate the company's focus on elevating its manufacturing capabilities. The strategic collaboration with Recipharm also indicates a forward-thinking approach, positioning Scinai to better serve its clientele with enhanced technological solutions. Such advancements are pivotal as Scinai aims to be at the forefront of biotech manufacturing innovation, where quality, efficiency, and compliance are paramount.